Last updated: September 2, 2026
Anidulafungin is a mature echinocandin antifungal that has moved from a premium hospital brand to a generic injectable product. Pfizer’s Eraxis franchise no longer has the commercial profile of a growth product, and public filings do not report standalone Eraxis revenue. Current economics are driven by generic tender pricing, hospital formulary position, supply reliability, and competition from caspofungin, micafungin, liposomal amphotericin B, azole antifungals, and the newer long-acting agent rezafungin.
What is anidulafungin and how is it used?
Anidulafungin is an intravenous echinocandin used for invasive Candida infections and esophageal candidiasis. The FDA approved Eraxis in 2006. The product inhibits beta-(1,3)-D-glucan synthase, disrupting fungal cell-wall formation. It has no oral formulation and is administered by intravenous infusion.
| Attribute |
Anidulafungin |
| Brand |
Eraxis |
| Active ingredient |
Anidulafungin |
| Drug class |
Echinocandin antifungal |
| Original sponsor |
Vicuron Pharmaceuticals |
| Current branded owner |
Pfizer |
| FDA approval |
2006 |
| Main indications |
Candidemia, other Candida infections, esophageal candidiasis |
| Typical adult dose |
200 mg loading dose followed by 100 mg daily for invasive candidiasis; lower maintenance dosing for esophageal candidiasis |
| Administration |
Intravenous infusion |
| Biosimilar status |
Not applicable; anidulafungin is a small-molecule drug |
| Commercial status |
Mature generic injectable market |
The FDA label covers candidemia and other Candida infections, including intra-abdominal abscess and peritonitis. Treatment duration depends on clinical response and source control. IDSA guidelines identify echinocandins, including anidulafungin, as preferred initial therapy for many adults with candidemia or invasive candidiasis.[1][2]
When did anidulafungin lose exclusivity?
Anidulafungin’s commercial exclusivity expired after the product’s original patent and regulatory exclusivity periods ended. Eraxis is now exposed to generic competition in the United States and other major markets.
The product’s exclusivity profile followed the standard sequence for a small-molecule hospital drug:
- FDA approval in 2006 created the branded launch period.
- Patent protection extended the branded commercial period beyond regulatory exclusivity.
- Generic injectable products entered after the relevant patent barriers expired or became commercially nonblocking.
- Hospital and group-purchasing-organization contracts shifted demand toward lower-cost suppliers.
Eraxis was not a biologic, so it did not receive a biosimilar pathway or biologic reference-product exclusivity. Generic applicants could rely on an abbreviated new drug application once the applicable patents and regulatory barriers no longer blocked approval.
What is the Orange Book status of Eraxis?
The FDA Orange Book remains the controlling source for current listed patents, exclusivity, and approved generic equivalents. Eraxis is an older small-molecule product with no meaningful remaining period of branded market exclusivity. Its current competitive risk is generic substitution rather than a pending late-stage patent cliff.[3]
The relevant commercial conclusion is that anidulafungin has transitioned from an originator-protected product to an off-patent hospital injectable. Any residual patent value would depend on a specific active listing, formulation claim, manufacturing claim, or enforceable use claim. The core anidulafungin product is no longer protected by a commercially significant exclusivity position.
What patents protect anidulafungin?
The original anidulafungin estate covered the compound, related echinocandin chemistry, pharmaceutical compositions, and methods of treating fungal infections. The estate originated with Vicuron and related predecessor research programs before Pfizer acquired Vicuron in 2005.
Patent protection historically mattered in four areas:
- The anidulafungin molecule and its chemical structure.
- Pharmaceutical compositions containing the active ingredient.
- Manufacturing and purification processes.
- Treatment of Candida and other fungal infections.
Those rights supported Eraxis during its branded period. Their commercial importance has declined as the principal composition-of-matter and product protection periods ended.
What formulations are protected by anidulafungin patents?
The marketed formulation is a sterile lyophilized powder for intravenous administration. Generic competition focuses on matching the reference product’s active ingredient, strength, reconstitution characteristics, stability, and injectable presentation.
Formulation barriers are limited compared with products that rely on complex delivery devices, depot technology, liposomal encapsulation, or controlled release. Anidulafungin’s hospital-use formulation creates manufacturing requirements, but it does not provide the same level of protection as a novel delivery platform.
Manufacturers still face technical barriers involving:
- Sterile manufacturing.
- Lyophilization.
- Vial filling and packaging.
- Reconstitution performance.
- Stability during storage and transport.
- Control of particulate matter and endotoxins.
- Consistency of infusion preparation.
These requirements can reduce the number of reliable suppliers, but they do not restore branded exclusivity.
How many patents cover anidulafungin?
The historical patent estate included multiple patent families rather than a single right. The exact number of active and expired patents depends on jurisdiction, patent-family treatment, terminal disclaimers, patent-term adjustments, pediatric extensions, and whether expired process or use patents are counted.
For current market analysis, the material distinction is between historical patent breadth and remaining enforceable commercial protection. The latter is limited. No public evidence indicates that anidulafungin has a current patent estate capable of preserving premium pricing for the core intravenous product in the United States.
What is the FDA regulatory status of anidulafungin?
Anidulafungin is FDA-approved and marketed as an injectable antifungal. Eraxis was approved under NDA 021632. Generic products are approved through the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence or other applicable requirements.
| Regulatory factor |
Current implication |
| FDA approval |
Established |
| Clinical use |
Standard hospital antifungal therapy |
| Approval pathway for generics |
ANDA |
| Regulatory exclusivity |
Expired |
| Biosimilar pathway |
Not applicable |
| Pediatric exclusivity |
Historical issue only; no current commercial effect |
| Risk of regulatory replacement |
Low for the existing indication set |
| Manufacturing sensitivity |
High because the product is sterile and injectable |
The primary regulatory risk is not withdrawal of approval. It is manufacturing disruption, quality enforcement, or a supplier exit that reduces availability.
Which companies compete with anidulafungin?
Anidulafungin competes in a hospital antifungal market where clinicians generally choose among echinocandins based on formulary contracts, clinical familiarity, dosing, liver and kidney considerations, drug interactions, and supply.
| Competitor |
Class |
Main competitive position |
| Micafungin |
Echinocandin |
Broad hospital use; established generic competition |
| Caspofungin |
Echinocandin |
Long-standing standard therapy; generic availability |
| Rezafungin |
Long-acting echinocandin |
Weekly dosing and outpatient potential |
| Liposomal amphotericin B |
Polyene |
Broad antifungal spectrum; toxicity limits use |
| Fluconazole |
Azole |
Low-cost step-down and susceptible-organism therapy |
| Voriconazole and isavuconazole |
Azoles |
Important for selected mold and invasive fungal infections |
Rezafungin is the most relevant newer echinocandin competitor. The FDA approved Rezzayo in 2023 for candidemia and invasive candidiasis in adults with limited or no alternative treatment options.[4] Its once-weekly administration offers a potential advantage in outpatient care and reduces daily infusion requirements, but its initial label and pricing position differ from generic anidulafungin.
How does anidulafungin compare with micafungin and caspofungin?
Anidulafungin has a favorable pharmacokinetic profile because it undergoes slow chemical degradation and does not depend primarily on hepatic metabolism. This can simplify use in patients with hepatic dysfunction. It remains an intravenous product, like the other traditional echinocandins.
| Factor |
Anidulafungin |
Micafungin |
Caspofungin |
| Daily IV dosing |
Yes |
Yes |
Yes |
| Generic competition |
Yes |
Yes |
Yes |
| Hepatic metabolism concern |
Relatively limited |
Present |
Present |
| Renal dose adjustment |
Generally not required |
Generally not required |
Generally not required |
| Hospital familiarity |
High |
High |
High |
| Commercial pricing |
Generic, pressured |
Generic, pressured |
Generic, pressured |
Clinical differentiation is narrower than it was during the branded era. Procurement economics often determine product selection when clinical outcomes are broadly comparable.
What financial trajectory has anidulafungin followed?
Anidulafungin’s financial trajectory has four stages.
1. Branded launch and adoption
Eraxis entered the market as a differentiated hospital antifungal during a period when echinocandins were gaining use for invasive Candida infections. The product benefited from strong inpatient demand, guideline support, and the clinical value of an echinocandin option.
Pfizer reported Eraxis within broader pharmaceutical sales categories rather than as a consistently disclosed standalone revenue line. Public filings therefore do not provide a reliable annual Eraxis revenue series.[5]
2. Mature branded sales
During the mature-brand period, demand was supported by:
- Intensive-care-unit use.
- Hematology and oncology patients.
- Central-line-associated candidemia.
- Surgical and intra-abdominal infections.
- Use when azole resistance or intolerance limited alternatives.
The product remained commercially relevant, but its growth depended on hospital volume rather than expansion into a large outpatient market.
3. Patent expiry and generic erosion
Generic entry changed the financial model. Price competition became more important than market expansion. Hospitals and purchasing organizations could seek lower prices from multiple injectable suppliers, reducing the value of the Eraxis brand.
The likely commercial effects were:
- Rapid decline in branded unit share.
- Lower average selling prices.
- Greater rebate and contract pressure.
- Reduced promotional investment.
- More procurement-driven switching.
- Greater exposure to manufacturing and shortage events.
4. Generic steady state
The current market is a low-growth, mature injectable segment. Revenue is tied to treated inpatient days, Candida incidence, clinical guidelines, hospital census, and supplier availability. Generic manufacturers can generate recurring sales, but margins depend on production scale, capacity utilization, procurement contracts, and the number of active competitors.
What drives the anidulafungin market?
The key market drivers are clinical need, hospital utilization, and supply economics.
Hospital and intensive-care demand
Invasive candidiasis is concentrated in critically ill and medically complex patients. Risk factors include intensive-care admission, major surgery, central venous catheters, broad-spectrum antibiotics, parenteral nutrition, and immunosuppression.[2]
Antifungal resistance
Rising azole resistance supports echinocandin use. Echinocandins remain important empiric and directed therapies when Candida susceptibility is uncertain or azole resistance is suspected.
Generic pricing
Price competition is the dominant commercial force. Anidulafungin competes against two other generic echinocandins, which limits pricing power unless one or more suppliers experience shortages.
Formulary economics
Hospitals may select one echinocandin as a preferred product and retain another for specific clinical circumstances. Contract awards can shift market share without changes in clinical guidelines.
Outpatient limitations
Daily intravenous administration limits the addressable outpatient market. Rezafungin’s weekly administration could capture selected step-down or outpatient cases, but anidulafungin retains an advantage where low acquisition cost and established inpatient protocols are the priorities.
What generic entry risks exist for anidulafungin?
Generic entry risk is largely realized rather than prospective. The product faces ongoing erosion from approved injectable equivalents rather than a future first-wave patent challenge.
The principal risks to branded or premium-priced anidulafungin are:
- Additional ANDA approvals.
- Hospital conversion to lower-priced equivalents.
- Contract loss at integrated delivery networks.
- Distributor substitution.
- Supplier consolidation followed by aggressive price competition.
- Product recalls or manufacturing interruptions affecting confidence.
- Clinical migration to weekly rezafungin in selected settings.
For generic manufacturers, the risk is different. A crowded injectable market can produce low margins, while sterile manufacturing failures can cause supply interruptions and regulatory costs.
What patent litigation and Paragraph IV challenges affect anidulafungin?
No major current Paragraph IV litigation involving the core anidulafungin product is a central market event. Paragraph IV litigation was most relevant before generic entry, when applicants could challenge listed patents to accelerate market access.
The current legal environment is defined by:
- Expired or commercially exhausted core patent protection.
- Limited value in litigating legacy composition claims.
- Potential disputes over manufacturing, labeling, or specific formulation claims.
- ANDA-related litigation only if a new patent listing creates a blocking issue.
There is no biosimilar litigation pathway because anidulafungin is a small molecule.
What licensing deals shaped anidulafungin?
The major corporate transaction was Pfizer’s acquisition of Vicuron Pharmaceuticals in 2005. Pfizer obtained Eraxis and Vicuron’s anti-infective portfolio through that transaction.[6]
The acquisition gave Pfizer control of anidulafungin before FDA approval and allowed Eraxis to launch under a large pharmaceutical infrastructure. No later licensing transaction has materially changed the commercial structure of the anidulafungin market.
What geographic markets are most important?
The United States, Europe, Japan, and other high-income hospital markets remain the principal commercial regions for regulated anidulafungin products. Generic competition is more advanced in the United States and Europe, while branded, licensed, or locally manufactured versions may remain relevant in other markets.
Geographic value depends on:
- National reimbursement.
- Hospital tender systems.
- Local generic approvals.
- Import requirements.
- Sterile manufacturing capacity.
- Antifungal resistance patterns.
- Availability of competing echinocandins.
Emerging markets may have clinical demand but lower prices and greater reliance on tender procurement. This limits revenue even where patient volume is substantial.
How strong is the anidulafungin patent estate?
The historical estate was commercially useful, but the current estate is weak as a source of market exclusivity. The core intravenous product is mature, genericized, and clinically substitutable within the echinocandin class.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Historical value; no current core-market protection |
| Formulation protection |
Limited remaining commercial impact |
| Method-of-use protection |
Narrow and unlikely to block routine generic use |
| Manufacturing patents |
May create technical barriers but not broad exclusivity |
| Regulatory exclusivity |
Expired |
| Biosimilar barrier |
Not relevant |
| Current litigation leverage |
Low |
| Ability to sustain premium pricing |
Low |
What is the outlook for anidulafungin revenue?
Revenue should remain stable to declining in nominal terms, with unit demand supported by persistent invasive candidiasis incidence. The product is unlikely to produce material growth without a major change in delivery technology, pricing structure, or clinical positioning.
The most probable trajectory is:
- Flat or modestly declining hospital volumes.
- Continued erosion in branded revenue.
- Low generic prices.
- Periodic price increases during supply shortages.
- Stable clinical use as a daily intravenous echinocandin.
- Selective substitution by rezafungin in outpatient or weekly-dosing settings.
For Pfizer, Eraxis is unlikely to represent a material revenue contributor relative to the company’s major oncology, immunology, vaccine, and specialty-care products. For generic manufacturers, the opportunity is a recurring hospital product with limited differentiation and meaningful execution risk.
Key Takeaways
- Anidulafungin is an established intravenous echinocandin marketed originally as Pfizer’s Eraxis.
- FDA approval dates to 2006, and regulatory exclusivity has expired.
- The product is now exposed to generic competition and hospital tender pricing.
- No biosimilar pathway applies because anidulafungin is a small molecule.
- The historical patent estate covered the compound, formulations, uses, and manufacturing, but it no longer provides material core-market exclusivity.
- Public company filings do not report standalone Eraxis revenue, so product-specific financial exposure cannot be measured from Pfizer disclosures alone.
- Micafungin and caspofungin are the closest generic competitors.
- Rezafungin is the principal newer echinocandin threat because of weekly dosing.
- Current commercial value rests on hospital demand, low acquisition cost, supply reliability, and formulary contracts.
- The expected financial profile is mature, low-growth, and vulnerable to price erosion.
FAQs About Anidulafungin Market and Exclusivity
Is anidulafungin still under patent protection?
The core anidulafungin product is no longer protected by a commercially significant period of market exclusivity in the United States. Historical compound and product patents supported Eraxis before generic entry.
Is anidulafungin available as a generic?
Yes. Anidulafungin is available as generic intravenous injection from multiple manufacturers and competes with generic caspofungin and micafungin.
Can anidulafungin be replaced by rezafungin?
Rezafungin can be an alternative in appropriate adult patients, particularly where weekly administration has clinical or operational value. It does not replace anidulafungin across all inpatient cases because labeling, price, formulary policy, and patient characteristics differ.
Does anidulafungin have an oral version?
No. Anidulafungin is administered intravenously. Oral step-down therapy may involve an azole when the patient is clinically stable and the organism is susceptible.
What would cause anidulafungin prices to rise after generic entry?
The main triggers would be sterile-manufacturing problems, product recalls, supplier exits, raw-material constraints, or a shortage affecting competing echinocandins. These events can temporarily reduce supply and increase contract prices.
References
-
U.S. Food and Drug Administration. (2006). Eraxis (anidulafungin) prescribing information. FDA.
-
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1-e50.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
U.S. Food and Drug Administration. (2023). Rezzayo (rezafungin for injection) prescribing information. FDA.
-
Pfizer Inc. (2006-2023). Annual reports and Form 10-K filings. Pfizer.
-
Pfizer Inc. (2005). Pfizer to acquire Vicuron Pharmaceuticals. Pfizer investor and corporate communications materials.
